Literature DB >> 24242938

Influence of short-chain cell-penetrating peptides on transport of doxorubicin encapsulating receptor-targeted liposomes across brain endothelial barrier.

Gitanjali Sharma1, Amit Modgil, Tiecheng Zhong, Chengwen Sun, Jagdish Singh.   

Abstract

PURPOSE: To investigate the influence of different cell penetrating peptides (CPPs-TAT, Penetratin and Mastoparan), on the transport of doxorubicin encapsulating transferrin (Tf)-liposomes across brain endothelial barrier, in vitro and in vivo.
METHODS: The cellular uptake of dual-functionalized, (Tf-CPP), liposomes into various tumor cells was assessed using HPLC. The transport of liposomes was also measured across a robust 3D brain tumor model constructed using chitosan-PLGA scaffolds. The growth of tumor cells was monitored using H&E staining and the fully grown tumor scaffolds were visualized using SEM. The tumor scaffolds were combined with the culture inserts carrying tightly packed brain endothelial cells. The in vitro and in vivo transport of drug (using Tf-CPP-liposomes) across the brain endothelial barrier was determined by extraction of the drug from cells and tissues followed by analysis using HPLC.
RESULTS: The results demonstrated improved delivery of doxorubicin using dual-functionalized liposomes versus the single ligand or unmodified liposomes. Among different Tf-CPP-liposomes, the Tf-Penetratin liposomes showed efficient cellular transport of the encapsulated drug (approximately 90-98%) and maximum translocation of the drug across the brain endothelial barrier (approximately 15% across in vitro and 4% across in vivo BBB). The Tf-Penetratin and Tf-TAT liposomes demonstrated excellent cellular biocompatibility and no hemolytic activity upto 200nM phospholipid concentration.
CONCLUSIONS: The Tf-CPP liposomes showed efficient translocation of the anticancer drug across the brain endothelial barrier. In addition, an absolute and robust in vitro brain tumor model was successfully constructed to overcome the practical intricacies of developing a successful in vivo orthotopic brain tumor model.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24242938     DOI: 10.1007/s11095-013-1242-x

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  53 in total

Review 1.  In vivo characteristics of cationic liposomes as delivery vectors for gene therapy.

Authors:  Sandrine A L Audouy; Lou F M H de Leij; Dick Hoekstra; Grietje Molema
Journal:  Pharm Res       Date:  2002-11       Impact factor: 4.200

Review 2.  Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease.

Authors:  Celeste Roney; Padmakar Kulkarni; Veera Arora; Peter Antich; Frederick Bonte; Aimei Wu; N N Mallikarjuana; Sanjeev Manohar; Hsiang-Fa Liang; Anandrao R Kulkarni; Hsing-Wen Sung; Malladi Sairam; Tejraj M Aminabhavi
Journal:  J Control Release       Date:  2005-10-24       Impact factor: 9.776

3.  Electrical resistance measurements on cerebral capillary endothelial cells--a new technique to study small surface areas.

Authors:  M Erben; S Decker; H Franke; H J Galla
Journal:  J Biochem Biophys Methods       Date:  1995-11

4.  Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity.

Authors:  C Rousselle; M Smirnova; P Clair; J M Lefauconnier; A Chavanieu; B Calas; J M Scherrmann; J Temsamani
Journal:  J Pharmacol Exp Ther       Date:  2001-01       Impact factor: 4.030

5.  Central analgesic actions of loperamide following transient permeation of the blood brain barrier with Cereport (RMP-7).

Authors:  D F Emerich; P Snodgrass; M Pink; F Bloom; R T Bartus
Journal:  Brain Res       Date:  1998-08-10       Impact factor: 3.252

6.  The use of inhibitors to study endocytic pathways of gene carriers: optimization and pitfalls.

Authors:  Dries Vercauteren; Roosmarijn E Vandenbroucke; Arwyn T Jones; Joanna Rejman; Joseph Demeester; Stefaan C De Smedt; Niek N Sanders; Kevin Braeckmans
Journal:  Mol Ther       Date:  2009-12-15       Impact factor: 11.454

Review 7.  Long-term survival with glioblastoma multiforme.

Authors:  Dietmar Krex; Barbara Klink; Christian Hartmann; Andreas von Deimling; Torsten Pietsch; Matthias Simon; Michael Sabel; Joachim P Steinbach; Oliver Heese; Guido Reifenberger; Michael Weller; Gabriele Schackert
Journal:  Brain       Date:  2007-09-04       Impact factor: 13.501

8.  Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Surveillance Epidemiology and End Results.

Authors:  Dawn Elizabeth McNeil; Timothy R Coté; Limin Clegg; Lucy Balian Rorke
Journal:  Med Pediatr Oncol       Date:  2002-09

9.  In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis.

Authors:  Dagmar Fischer; Youxin Li; Barbara Ahlemeyer; Josef Krieglstein; Thomas Kissel
Journal:  Biomaterials       Date:  2003-03       Impact factor: 12.479

10.  Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles.

Authors:  Hae Yun Nam; Seok Min Kwon; Hyunjin Chung; Seung-Young Lee; Seung-Hae Kwon; Hyesung Jeon; Yoonkyung Kim; Jae Hyung Park; Joon Kim; Songwook Her; Yu-Kyoung Oh; Ick Chan Kwon; Kwangmeyung Kim; Seo Young Jeong
Journal:  J Control Release       Date:  2009-02-03       Impact factor: 9.776

View more
  20 in total

1.  Delivery and tracking of quantum dot peptide bioconjugates in an intact developing avian brain.

Authors:  Rishabh Agarwal; Miriam S Domowicz; Nancy B Schwartz; Judy Henry; Igor Medintz; James B Delehanty; Michael H Stewart; Kimihiro Susumu; Alan L Huston; Jeffrey R Deschamps; Philip E Dawson; Valle Palomo; Glyn Dawson
Journal:  ACS Chem Neurosci       Date:  2015-03-05       Impact factor: 4.418

Review 2.  Modifications of natural peptides for nanoparticle and drug design.

Authors:  Andrew P Jallouk; Rohun U Palekar; Hua Pan; Paul H Schlesinger; Samuel A Wickline
Journal:  Adv Protein Chem Struct Biol       Date:  2015-03-12       Impact factor: 3.507

3.  Dual Functionalized 5-Fluorouracil Liposomes as Highly Efficient Nanomedicine for Glioblastoma Treatment as Assessed in an In Vitro Brain Tumor Model.

Authors:  Sushant Lakkadwala; Jagdish Singh
Journal:  J Pharm Sci       Date:  2018-07-25       Impact factor: 3.534

4.  Revisiting intra-arterial drug delivery for treating brain diseases or is it "déjà-vu, all over again"?

Authors:  Shailendra Joshi; Jason A Ellis; Charles W Emala
Journal:  J Neuroanaesth Crit Care       Date:  2014-05

5.  Dual functionalized liposomes for efficient co-delivery of anti-cancer chemotherapeutics for the treatment of glioblastoma.

Authors:  Sushant Lakkadwala; Bruna Dos Santos Rodrigues; Chengwen Sun; Jagdish Singh
Journal:  J Control Release       Date:  2019-06-26       Impact factor: 9.776

6.  In vitro and in vivo optimization of liposomal nanoparticles based brain targeted vgf gene therapy.

Authors:  Sanjay Arora; Jagdish Singh
Journal:  Int J Pharm       Date:  2021-09-20       Impact factor: 5.875

Review 7.  Nanomaterial-based blood-brain-barrier (BBB) crossing strategies.

Authors:  Jinbing Xie; Zheyu Shen; Yasutaka Anraku; Kazunori Kataoka; Xiaoyuan Chen
Journal:  Biomaterials       Date:  2019-09-14       Impact factor: 12.479

8.  Quantification of kinetic rate constants for transcytosis of polymeric nanoparticle through blood-brain barrier.

Authors:  Aminul Islam Khan; Qian Lu; Dan Du; Yuehe Lin; Prashanta Dutta
Journal:  Biochim Biophys Acta Gen Subj       Date:  2018-08-31       Impact factor: 3.770

9.  Biodistribution of TAT or QLPVM coupled to receptor targeted liposomes for delivery of anticancer therapeutics to brain in vitro and in vivo.

Authors:  Sushant Lakkadwala; Bruna Dos Santos Rodrigues; Chengwen Sun; Jagdish Singh
Journal:  Nanomedicine       Date:  2019-10-25       Impact factor: 5.307

Review 10.  Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications.

Authors:  Christopher D Spicer; Coline Jumeaux; Bakul Gupta; Molly M Stevens
Journal:  Chem Soc Rev       Date:  2018-05-21       Impact factor: 54.564

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.